Hoth Therapeutics Enters Partnership With The Department Of Veterans Affairs To Develop Obesity Treatment

(MENAFN- PR Newswire)

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University

Hoth Also Expands Its' Intellectual Property to Further Its' market Opportunity for HT-001

NEW YORK, Dec. 26, 2024 /PRNewswire/ --
Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA). This agreement provides Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University.

The licensed technology centers on "Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions," a groundbreaking innovation aimed at addressing critical challenges in treating obesity and associated health conditions. This agreement underscores Hoth Therapeutics' commitment to advancing transformative healthcare solutions.

Under the terms of the agreement, Hoth Therapeutics will have exclusive rights to develop, market, and commercialize products and processes derived from the licensed patents. The VA and Emory University have granted Hoth this license to further develop the technology with the goal of ensuring the benefits of this innovation are accessible to the widest audience possible.

"We are honored to collaborate with the VA and Emory University to bring this cutting-edge technology to market," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "This partnership represents a significant milestone in our efforts to address obesity and related health conditions with innovative, science-driven solutions. We look forward to advancing this critical work to improve the lives of patients worldwide."

The agreement includes a comprehensive development plan, ensuring the continued progress of this technology from the research phase through commercialization. Hoth Therapeutics plans to leverage its expertise and resources to bring the licensed products to the point of practical application while adhering to rigorous development benchmarks.

This collaboration exemplifies Hoth's dedication to fostering partnerships that advance scientific discoveries into therapeutic solutions. The company remains steadfast in its mission to improve patient outcomes and address unmet medical needs.

Hoth has also entered into an agreement to further protect its intellectual property by signing an LOI to acquire additional provisional patent protection for its lead therapeutic HT-001. The additional intellectual property expands HT-001's reach to other cancer therapeutics.

About Hoth Therapeutics, Inc.

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing
innovative, impactful, and ground-breaking treatments with a goal to improve patient quality
of life. We are a catalyst in early-stage pharmaceutical research and development, elevating
drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach,
we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek
out and investigate therapeutics that hold immense potential to create breakthroughs and
diversify treatment options. To learn more, please visit .

Forward-Looking
Statement

This
press
release
includes forward-looking
statements
based upon
Hoth's
current expectations,
which
may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates
and
any
other
product candidates
we
may
develop,
and
the
labeling under
any
approval we
may obtain;
the
timing
and
costs
of
clinical
trials, and
the
timing and
costs
of
other
expenses;
market
acceptance of
our
products;
the
ultimate
impact of
any
health
epidemic,
on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; our cash needs and financing plans; and the long-term value of Bitcoin. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual
results
may
differ
materially
from
those
indicated
by
these
forward-looking
statements
as
a
result
of various
important
factors,
including,
without
limitation, market
conditions, risks inherent with investing in Bitcoin, including Bitcoin's volatility and risk of implementing a new Bitcoin treasury strategy,
and
the factors
described
in
the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-Kas amended or supplemented by Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC
Email:
[email protected]

Phone:
(678) 570-6791

SOURCE Hoth Therapeutics, Inc.

MENAFN28122024003732001241ID1109036650